Key factors
sym | MRK |
exch | US |
MCap | 317.21B |
Beta | 0.398 |
PE Ratio | 894.5 |
EPS | 0.14 |
Div | 2.92 |
Div Yld | 2.459 |
Div date | 2024-03-14 |
Yesterday
sym | MRK |
exch | US |
close | 130.72 |
50 Day MA | 126.05 |
200 Day MA | 112.57 |
52 Week High | 133.1 |
52 Week Low | 97.80 |
Target Price | 137.02 |
Market Cap Mln | 317.21K |
Share statistics
Shares Outstanding | 2.533B |
Shares Float | 2.527B |
Percent Institutions | 78.56 |
PercentInsiders | 0.049 |
SharesShort | 19.59M |
Short Ratio | 1.77 |
Shares Short Prior Month | 16.60M |
Short Percent | 0.769 |
Income
Revenue TTM | 60.11B |
Revenue Per Share TTM | 23.69 |
Quarterly Revenue Growth YOY | 5.799 |
Gross Profit TTM | 42.07B |
EBITDA | 8.297B |
Diluted Eps TTM | 0.14 |
Quarterly Earnings Growth YOY | 45.30 |
earning
Operating Margin TTM | 0.8th |
PEGRatio | 0.100 |
Trailing PE | 894.5 |
EPS Estimate Current Quarter | 1.94 |
EPS Estimate Current Year | 8.56 |
EPS Estimate Next Quarter | 2.11 |
EPS Estimate Next Year | 9.8 |
Earnings Share | 0.14 |
Dividend
Forward Annual Dividend Rate | 3.08 |
Forward Annual Dividend Yield | 2.459 |
Payout Ratio | 1.999 |
Dividend Date | 2024-04-05 |
Last Split Date | 2021-06-03 |
Last Split Factor | 1048:1000 |
business
Enterprise Value Ebitda | 50.16 |
Enterprise Value Revenue | 5.763 |
Book Value /share | 14.84 |
Price Book MRQ | 8.475 |
Price Sales TTM | 5.298 |
ProfitMargin | 0.006 |
ReturnOnAssetsTTM | 0.026 |
ReturnOnEquityTTM | 0.009 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Codes
ISIN | US58933Y1055 |
CIK | 310158 |
Code | MRK |
CUSIP | 589339209 |
Employer Id Number | 22-1918501 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NYSE |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
ForwardPE | 14.68 |
Full Time Employees | 70000 |
IPODate | 1978-01-13 |
International Domestic | Domestic |
MostRecent Quarter | 2024-03-31 |
Contact
Name | Merck & Company Inc |
Address | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 |
Country Name | USA |
Phone | 908 740 4000 |
Web URL | https://www.merck.com |
Logo URL | /img/logos/US/mrk.png |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.